PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This may best be achieved by large pharma companies, with their combined $200bn annual R&D budget, compared to smaller companies that are relying on external investment.

Biopharma 111

Biopharma Pharma Marketing Management 111

Pharmaceutical Technology

SEPTEMBER 13, 2022

The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product. The PharmaLex takeover will build upon the current European presence of AmerisourceBergen in pharmaceutical supply and biopharma manufacturer services expertise.

Biopharma 52

Biopharma Manufacturing Pharmaceutical manufacturing Consulting 52

MedCity News

NOVEMBER 22, 2023

With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business. Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized.

Prospecting 103

Prospecting Biopharma Pharma 103

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., This is supported by epidemiology data from Evaluate Pharma. Europe, and parts of Asia.

Marketing 59

Marketing Biopharma Government Pharma 59

MedCity News

JUNE 29, 2023

Eli Lilly is expanding its diabetes prospects by acquiring cell therapy developer Sigilon Therapeutics. The two companies are already partners in the development of a type 1 diabetes cell therapy currently in preclinical development.

Prospecting 77

Prospecting Biopharma Pharma 77

MedCity News

APRIL 17, 2023

The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years. Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders.

Medicine 89

Medicine Prospecting Leads Biopharma 89

pharmaphorum

DECEMBER 16, 2022

The Japanese pharma says it will now start talking to regulatory authorities around the world about potential marketing applications for zolbetuximab as a first-line treatment for patients with locally advanced unresectable or metastatic gastric and gastro-oesophageal (GEJ) cancer. Other companies developing claudin 18.2-targeted

Leads 56

Leads Biopharma Prospecting Patients 56

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

MAY 8, 2024

As companies face the prospect of major revenue challenges over the next few years, securing inorganic growth through strategic alliances is increasingly attractive. As pharmas are increasingly selective about how they spend their money, biotechs would benefit from aligning their strengths with pharma companies’ priorities.

Pharma 59

Pharma Biopharma Prospecting Competition 59

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? I believe this is going to be an emerging trend in the market.

Manufacturing 78

Manufacturing Food and Drug Administration Biopharma Marketing 78

European Pharmaceutical Review

OCTOBER 27, 2022

Ahead of the world’s largest pharma event, CPHI Frankfurt – hosted at the Frankfurt Messe (1-3 November, 2022) – part i of the CPHI Annual Report looks ahead at the opportunities for biologics outsourcing and contract manufacturing organisastions (CMOs) in 2023. percent in 2022.

Biopharma 81

Biopharma Manufacturing Pharmacology Training 81

Clarivate

DECEMBER 14, 2023

A long winter for biotech financing: Capital scarcity is likely to continue as prospective investors and partners remain cautious, due to rising interest rates and concerns around externalities such as government initiatives to contain healthcare costs and global geopolitical conflicts. Those days are past, for the foreseeable future.

Pharma 111

Pharma Pharmacology Government Healthcare 111

Clarivate

FEBRUARY 28, 2023

“A Hospital-Based Five-Year Prospective Study on the Prevalence of Leber’s Hereditary Optic Neuropathy with Genetic Confirmation.” . “Leber Hereditary Optic Neuropathy: Case Report and Literature Review.” ” Cureus; V.12; 4; 4/20/2020; DOI:10.7759/cureus.7745 7745 [4] Gowri P et al.

Prescription 98

Prescription Patients Pharmacology Healthcare 98

Pharmaceutical Technology

MARCH 24, 2023

GC Biopharma is also running a Phase III trial for its live-attenuated vaccine GC-3107A to replace BCG. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Pharma 64

Pharma Side effects Marketing Biopharma 64

Pharmaceutical Technology

MARCH 21, 2023

In this month’s edition, which covers events from late January to early March, manufacturing contract-related data from GlobalData’s PharmSource reports and news from GlobalData’s Pharma Intelligence Center have been collated to identify stakeholders at the center of new developments.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

JANUARY 15, 2023

In order to get a therapy to the market, pharma companies often outsource the drug manufacturing to specialist contract manufacturing organizations (CMOs). While Catalent Inc and PCI Pharma Services are in charge of the solid dose and packaging of Lupkynis, Lonza is manufacturing the small molecule API.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52

Pharmaceutical Technology

JUNE 16, 2023

Synthetic biology biopharma Biostar Pharma announced is ready to advance its utidelone injectable (UTD1) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), following approval from the US Food and Drug Administration (FDA) for the study.

FDA 52

FDA Food and Drug Administration Patients Marketing 52

Pharmaceutical Technology

APRIL 16, 2023

This is an exciting prospect: oncology, and immuno-therapy in particular, is a driving force behind biotech R&D, with new cancer therapies and molecules accounting for nearly 40% 1 of the industry’s development pipeline. Citeline Pharma Intelligence report – Pharma R&D Annual Review 2022: Navivating the Landscape 2.

Medical 52

Medical Medicine Patients Manufacturing 52

Pharmaceutical Technology

FEBRUARY 27, 2023

To identify key events from late December to late January, this news service collated manufacturing contract-related data from PharmSource reports, and news from GlobalData’s Pharma Intelligence Center, to identify participants that are likely to experience an impact following the news.

Manufacturing 52

Manufacturing Pharmaceutical Pharma FDA 52

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 billion by 2028.

Manufacturing 52

Manufacturing Marketing Medicine Transportation 52